Tag:
AstraZeneca
Latest Headlines
Latest Headlines
AstraZeneca inks two pacts worth $831M
The U.K.'s AstraZeneca has signed two new licensing pacts. It is paying Palatin Technologies $10 million up front and up to $300 million in regulatory and sales milestones to develop obesity drugs. The pact covers the commercialization of small molecule compounds that target melanocortin receptors. Both companies will collaborate on the science while AstraZeneca covers the cost of …
Press Release: AstraZeneca Makes $100M Research Investment In Boston
Press Release: AstraZeneca Makes $100M Research Investment In Boston
AstraZeneca to invest $100M in R&D site
AstraZeneca is pumping $100 million into its research center in Waltham, MA to boost its R&D efforts for infectious diseases and cancer research. Construction on a 132,000-square-foot facility will begin soon and the facility will open in mid-2009. The expansion will allow AstraZeneca to add 100 more researchers to the 400 it already employs at the research complex. Since the opening of AstraZeneca R&D Boston, scientists there have discovered three potential drugs that are …
DEALS: AstraZeneca, BMS ink diabetes drug pact
AstraZeneca, BMS ink diabetes drug pact
FEATURE: Forbion Capital sees new approach to biotech investing
Filling the gap By John Carroll Pausing between meetings at the JP Morgan Healthcare deal-fest in San Francisco this week, Forbion Capital managing partner Bart Bergstein was clearly relishing the action. Earlier this week, Forbion Capital announced a €200 million venture fund for the life sciences field with the spin-off of the …
Press Release: Bristol-Myers Squibb, AstraZeneca Announce Worldwide Collaboration on Diabetes Compounds
Press Release: Bristol-Myers Squibb, AstraZeneca Announce Worldwide Collaboration on Diabetes Compounds
AstraZeneca inks billion-dollar pact on diabetes drugs
In what's being billed as an unusual partnership between drug giants, AstraZeneca has agreed to pay Bristol-Myers Squibb $100 million up front and up to $950 million more in milestones to partner up on two new diabetes drugs. AstraZeneca has also agreed to take on 75 percent of the development costs of both late-stage compounds, saxagliptin and dapagliflozin. Global sales and revenue on both products are to be split. Otsuka Pharmaceutical retains the Japanese rights to …
Press Release: Dynavax Reports Interim TOLAMBA Ragweed Allergy Results From DARTT Trial
Press Release: Dynavax Reports Interim TOLAMBA Ragweed Allergy Results From DARTT Trial
ALSO NOTED: Dynavax shares slump on inconclusive trial; iCo licenses rights to CAT-213; and much more...
> The big loser among biotech companies this morning is Dynavax Technologies, which saw its shares slump 26 percent after it announced that it was unable to determine the effectiveness of its ragweed allergy therapy in a clinical trial. The culprit: The absence of ragweed allergies among the volunteers. Release > Canada's iCo Therapeutics has licensed the rights to develop CAT-213, an antibody currently being studied for …
Press Release: AtheroGenics to Present at JPMorgan Healthcare Conference
Press Release: AtheroGenics to Present at JPMorgan Healthcare Conference
